Document is current

Article History

Received: 5 May 2022

Accepted: 21 February 2023

First Online: 2 March 2023

Competing interests

: K.T. has a patent with a patent (Patent No. JP6967260) and a patent (Patent No. JP6936496). Outside the submitted work, K.T. reports his position as CEO of Tsubota Laboratory, Inc., Tokyo, Japan, a company working on treatments, preventive agents, and medical devices for DED. Y.O. has a patent in Japan (Patent No. 4966019; Title: Topical application and oral intake of tranilast for the treatment of cGVHD-related dye eye disease). Y.O. and K.T. have patent application numbers JP 2017–018643, published as JPA2017-178922. Y.O., E. S., and K.T. have patent application numbers JP2018-510646 published as WO2017/175808. E.S. has a grant from the Japanese Ministry of Education, Science, Sports, and Culture 21K18394 and Bristol Myers Squibb. The other authors received no financial support or additional benefit from commercial sources for the work reported in this manuscript. Moreover, the authors have no financial interests that may create a potential conflict or the appearance of a conflict of interest regarding this work.